Exelixis Eyes Liver Cancer OK To Help Drive Cabometyx Sales
Executive Summary
Exelixis is looking to get its kidney cancer drug Cabometyx approved for hepatocellular carcinoma as well, but the therapy's long-term success is reliant on combinations with checkpoint inhibitors
You may also be interested in...
With Phase III Failure, Exelixis Drops First-Line Liver Cancer Plans For Cabometyx
While a combo of Cabometyx and Roche’s Tecentriq earlier demonstrated a progression-free survival benefit compared to Nexavar, a subsequent readout showed no overall survival benefit.
Exelixis: NCCN Change Supports Broader Use Of Cabometyx In Kidney Cancer
Latest set of oncology clinical practice guidelines issued in September highlight Cabometyx as preferred treatment option.
C4XD Delisting Highlights Funding Frustration For UK Biotechs
The Manchester-based group has had enough of being undervalued in the public markets and is going private again.